In the latest close session, Novo Nordisk (NVO) was down 2.02% at $41.67. The stock's performance was behind the S&P 500's daily loss of 0.45%. At the same time, the Dow lost 1.21%, and the tech-heavy Nasdaq lost 0.01%. Shares of the drugmaker have depreciated by 6.96% over the course of the past month, underperforming the Medical sector's loss of 0.29%, and the S&P 500's loss of 2.43%. Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.8, marking a 21.57% fall compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $11.49 billion, showing a 2.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.